{"id":"NCT00426660","sponsor":"ViiV Healthcare","briefTitle":"Expanded Access Program for Maraviroc At Multiple Centers","officialTitle":"A Multicenter, Open Label, Expanded Access Trial Of Maraviroc","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2007-01-25","resultsPosted":"2011-10-17","lastUpdate":"2016-06-29"},"enrollment":1047,"design":{"allocation":"NON_RANDOMIZED","model":null,"masking":null,"primaryPurpose":"TREATMENT"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"maraviroc","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.","primaryOutcome":{"measure":"Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)","timeFrame":"Baseline up to Week 144","effectByArm":[{"arm":"Maraviroc","deltaMin":13.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":361,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","Costa Rica","Dominican Republic","France","Germany","Greece","Hong Kong","India","Ireland","Italy","Malaysia","Mexico","Netherlands","Portugal","Puerto Rico","Romania","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001050&StudyName=Expanded%20Access%20Program%20for%20Maraviroc%20At%20Multiple%20Centers"]},"adverseEventsSummary":{"seriousAny":{"events":139,"n":1032},"commonTop":["Diarrhoea","Bronchitis","Headache","Nausea","Pyrexia"]}}